SFPIA
ECYT

Stevens First Principles Investment Advisors’s Endocyte, Inc. Common Stock ECYT Stock Holding History

Stevens First Principles Investment Advisors’s Portfolio ECYT Stock Details ECYT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-800
Closed -$9K – 228
2013
Q4 		$9K Hold
800
– – 0.01% 185
2013
Q3 		$11K Sell
800
-700
-47% -$11.1K 0.01% 180
2013
Q2 		$20K Buy
+1,500
New +$20.2K 0.01% 165

Other funds holding ECYT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
PA
Pinnacle Associates New York $7.78B AUM 45.07% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
OIM
Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
RIM
RS Investment Management San Francisco, California $9.73B AUM 3.24% 1-Year Est. Return

Stevens First Principles Investment Advisors's ECYT Position: Q1 2014 in Review

Stevens First Principles Investment Advisors sold out of Endocyte, Inc. Common Stock (ECYT) in Q1 2014, closing a stake of 800 shares — an estimated $9K sold.

Stevens First Principles Investment Advisors first reported a position in ECYT in Q2 2013 and held it in 3 quarters. The position peaked at $20K in Q2 2013. 121 funds tracked by Wall St. Rank hold ECYT as of Q1 2014.

  • Stevens First Principles Investment Advisors reported no remaining Endocyte, Inc. Common Stock position as of Q1 2014 after selling out during the quarter.
  • Stevens First Principles Investment Advisors sold 800 Endocyte, Inc. Common Stock shares in Q1 2014, an estimated $9K.
  • Stevens First Principles Investment Advisors first reported a position in Endocyte, Inc. Common Stock in Q2 2013 and held it in 3 quarters.
  • Stevens First Principles Investment Advisors's Endocyte, Inc. Common Stock position peaked at $20K in Q2 2013.
  • 121 funds tracked by Wall St. Rank held Endocyte, Inc. Common Stock as of Q1 2014.

Based on Stevens First Principles Investment Advisors's 13F filing for Q1 2014, filed 15 May 2014.